论文部分内容阅读
目的:探析二联活菌联合曲美布汀治疗肠易激综合征的效果。方法:随机抽选2013年1月至2015年12月来本院就诊的100例肠易激综合征患者,分为两组,其中对照组患者实施常规治疗,观察组患者实施二联活菌联合曲美布汀进行治疗,统计分析与比较两组患者的临床治疗效果。结果:观察组患者的临床治疗有效率是96%,对照组是74%,差异具有统计学意义(P<0.05)。观察组患者的不良反应发生率是4%,对照组患者是0%,差异均无统计学意义(P>0.05)。结论:二联活菌联合曲美布汀联合治疗肠易激综合征的效果较为理想,在提高患者临床治疗效果的同时,又不增加患者的不良反应发生率,保持患者肠道菌群的稳定性,避免肠易激综合征的反复发作,保证患者的身体健康。
Objective: To investigate the effect of viable bacteria combined with trimebutine in the treatment of irritable bowel syndrome. Methods: A total of 100 patients with irritable bowel syndrome who came to our hospital from January 2013 to December 2015 were randomly selected and divided into two groups. Patients in the control group underwent routine treatment. Patients in the observation group were treated with combination of viable bacteria Trimebutine treatment, statistical analysis and comparison of two groups of patients with clinical treatment. Results: The effective rate of clinical treatment was 96% in observation group and 74% in control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions was 4% in the observation group and 0% in the control group, with no significant difference (P> 0.05). Conclusion: The combination of live viable bacteria and trimebutine in the treatment of irritable bowel syndrome is more effective in improving the clinical efficacy of patients without increasing the incidence of adverse reactions in patients and keeping the stability of intestinal flora in patients Sex, to avoid recurrent irritable bowel syndrome, to ensure the patient’s health.